An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV) negative squamous cell carcinoma of head and neck that have failed to respond to standard therapy, progressed despite standard therapy, for which standard therapy does not offer the potential for increased survival.

Start Date10 May 2017

Sponsor / Collaborator

Threshold Pharmaceuticals, Inc.

[+1]

NCT02598687 / WithdrawnPhase 1IIT

A Phase I Trial Testing TH-302, a Tumor-selective Hypoxia-Activated Cytotoxic Prodrug, in Combination With Preoperative Chemoradiotherapy in Patients With Distal Esophageal and Esophago-gastric Junction Adenocarcinoma

Open-label, single-center phase 1 study of an investigational agent TH-302 and standard chemoradiotherapy with a 3+3 dose escalation design through 3 dose levels.

Start Date01 Dec 2015

Sponsor / Collaborator

Maastro

[+2]

NCT02402062 / CompletedPhase 2IIT

A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)

The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.

Start Date11 May 2015

Sponsor / Collaborator

Pfizer Inc.

[+1]

100 Clinical Results associated with Evofosfamide

100 Translational Medicine associated with Evofosfamide

100 Patents (Medical) associated with Evofosfamide

126

Literatures (Medical) associated with Evofosfamide

01 Sep 2024·FREE RADICAL BIOLOGY AND MEDICINE

Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated prodrug

Article

Author: Yamamoto, Kazutoshi ; Krishna, Murali C ; Yasunori, Otowa ; Brender, Jeffrey R ; Crooks, Daniel R ; Kota, Yamashita ; Linehan, W Marston ; Kishimoto, Shun ; Levine, Mark

Hypoxic tumor microenvironments pose a significant challenge in cancer treatment. Hypoxia-activated prodrugs like evofosfamide aim to specifically target and eliminate these resistant cells. However, their effectiveness is often limited by reoxygenation after cell death. We hypothesized that ascorbate's pro-oxidant properties could be harnessed to induce transient hypoxia, enhancing the efficacy of evofosfamide by overcoming reoxygenation. To test this hypothesis, we investigated the sensitivity of MIA Paca-2 and A549 cancer cells to ascorbate in vitro and in vivo. Ascorbate induced a cytotoxic effect at 5 mM that could be alleviated by endogenous administration of catalase, suggesting a role for hydrogen peroxide in its cytotoxic mechanism. In vitro, Seahorse experiments indicated that the generation of hydrogen peroxide consumes oxygen, which is offset at later time points by a reduction in oxygen consumption due to hydrogen peroxide's cytotoxic effect. In vivo, photoacoustic imaging showed pharmacologic ascorbate treatment at sublethal levels triggered a complex, multi-phasic response in tumor oxygenation across both cell lines. Initially, ascorbate generated transient hypoxia within minutes through hydrogen peroxide production, via reactions that consume oxygen. This initial hypoxic phase peaked at around 150 s and then gradually subsided. However, at longer time scales (approximately 300 s) a vasodilation effect triggered by ascorbate resulted in increased blood flow and subsequent reoxygenation. Combining sublethal levels of i. p. Ascorbate with evofosfamide significantly prolonged tumor doubling time in MIA Paca-2 and A549 xenografts compared to either treatment alone. This improvement, however, was only observed in a subpopulation of tumors, highlighting the complexity of the oxygenation response.

01 Jul 2024·NUCLEAR MEDICINE AND BIOLOGY

[18F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response

Article

Author: Sorace, Anna G ; Larimer, Benjamin M ; McNeal, Kaytlyn C ; Reeves, Kirsten M ; Lapi, Suzanne E ; Song, Patrick N

CONTEXT:

Hypoxia within the tumor microenvironment is a critical factor influencing the efficacy of immunotherapy, including immune checkpoint inhibition. Insufficient oxygen supply, characteristic of hypoxia, has been recognized as a central determinant in the progression of various cancers. The reemergence of evofosfamide, a hypoxia-activated prodrug, as a potential treatment strategy has sparked interest in addressing the role of hypoxia in immunotherapy response. This investigation sought to understand the kinetics and heterogeneity of tumor hypoxia and their implications in affecting responses to immunotherapeutic interventions with and without evofosfamide.

PURPOSE:

This study aimed to investigate the influence of hypoxia on immune checkpoint inhibition, evofosfamide monotherapy, and their combination on colorectal cancer (CRC). Employing positron emission tomography (PET) imaging, we developed novel analytical methods to quantify and characterize tumor hypoxia severity and distribution.

PROCEDURES:

Murine CRC models were longitudinally imaged with [¹⁸F]-fluoromisonidazole (FMISO)-PET to quantify tumor hypoxia during checkpoint blockade (anti-CTLA-4 + and anti-PD1 +/- evofosfamide). Metrics including maximum tumor [¹⁸F]FMISO uptake (FMISOmax) and mean tumor [¹⁸F]FMISO uptake (FMISOmean) were quantified and compared with normal muscle tissue (average muscle FMISO uptake (mAvg) and muscle standard deviation (mSD)). Histogram distributions were used to evaluate heterogeneity of tumor hypoxia.

FINDINGS:

Severe hypoxia significantly impeded immunotherapy effectiveness consistent with an immunosuppressive microenvironment. Hypoxia-specific PET imaging revealed a striking degree of spatial heterogeneity in tumor hypoxia, with some regions exhibiting significantly more severe hypoxia than others. The study identified FMISOmax as a robust predictor of immunotherapy response, emphasizing the impact of localized severe hypoxia on tumor volume control during therapy. Interestingly, evofosfamide did not directly reduce hypoxia but markedly improved the response to immunotherapy, uncovering an alternative mechanism for its efficacy.

CONCLUSIONS:

These results enhance our comprehension of the interplay between hypoxia and immune checkpoint inhibition within the tumor microenvironment, offering crucial insights for the development of personalized cancer treatment strategies. Non-invasive hypoxia quantification through molecular imaging evaluating hypoxia severity may be an effective tool in guiding treatment planning, predicting therapy response, and ultimately improving patient outcomes across diverse cancer types and tumor microenvironments. It sets the stage for the translation of these findings into clinical practice, facilitating the optimization of immunotherapy regimens by addressing tumor hypoxia and thereby enhancing the efficacy of cancer treatments.

15 May 2024·CLINICAL CANCER RESEARCH

Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

Author: Ammons, W Steve ; Curd, John G ; Ferraro, Damien ; Sun, Jessica D ; Hart, Charles P ; Matteucci, Mark D ; Ahluwalia, Dharmendra ; Duan, Jian-Xin ; Liu, Qian ; Wang, Jingli ; Wang, Yan

News (Medical) associated with Evofosfamide

13 Feb 2024

·www.globenewswire.com

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations. “I am delighted to announce the addition of Nipun to the RAPT leadership team and welcome his wealth of experience in small molecule product development and commercial manufacturing,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “Nipun fills an important role as we advance zelnecirnon in late-stage clinical trials for inflammatory diseases and tivumecirnon in oncology indications, executing on our mission to bring promising drug candidates to patients with high unmet needs." Nipun brings over 27 years of extensive biopharmaceutical and drug development experience specializing in successful product development and commercial manufacturing. Most recently he served as Chief Corporate Officer at Astex Pharmaceuticals, Inc., where he oversaw the CMC, program management, legal and finance functions. Prior to Astex Pharmaceuticals, Inc., Nipun was Senior Vice President of Pharmaceutical Development and Manufacturing at Threshold Pharmaceuticals where he led the development of TH-302, a hypoxia activated prodrug developed to treat to multiple cancer types. Earlier in his career, Nipun held various roles encompassing drug delivery-based product development, clinical and commercial supply chain management, regulatory filings and product approvals. Nipun holds a Ph.D. in Pharmaceutical Sciences from the University of Maryland and an MBA from the Wharton School of Business. Nipun added, "I am pleased to join the RAPT leadership team during this exciting period. The company boasts a distinctive and diverse portfolio featuring two internally discovered compounds. Both zelnecirnon and tivumecirnon have demonstrated clinical proof of concept in their respective therapeutic areas, underlining the vast potential to make a positive impact for patients in both inflammatory diseases and oncology. I look forward to contributing to the continued advancement of these promising programs." About RAPT Therapeutics, Inc.RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, zelnecirnon (RPT193) and tivumecirnon (FLX475), each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development. Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com Media Contact:Aljanae Reynoldsareynolds@wheelhouselsa.com

Executive Change

03 Nov 2022

·www.prnewswire.com

ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference

HOUSTON, Nov. 3, 2022 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immune therapies, today announced that two poster presentations on its lead development program, IMGS-001, will be presented at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022), November 8-12, 2022, in Boston, MA. The posters will be available on the ImmunoGenesis website following the conference. Poster Presentation Details Development of IMGS-001, a novel anti-PD-L1/PD-L2 dual specific, multi-functional antibody, to treat immune excluded tumors Poster Number: 1333 November 10, 2022 Preclinical characterization of IMGS-001, a dual antagonist anti-PD-L1, anti-PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade Poster Number: 1378 November 11, 2022 About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor ImmunoGenesis' lead program is IMGS-001, a PD-L1/PD-L2 dual-specific inhibitor with an engineered cytotoxic effector function. As the first molecule to target PD-L2 in addition to PD-L1, IMGS-001 has the potential to shut down the entire PD-1 pathway, potentially providing superior blockade compared to other PD-1 or PD-L1 inhibitors. The built-in engineered effector function allows IMGS-001 to kill immunosuppressive cells that express PD-L1 and/or PD-L2. Preclinical data showed that IMGS-001 offered five times the response rate in cold tumors than currently available immunotherapies. Additionally, IMGS-001 can provide a foundation for add-on therapies. About ImmunoGenesis ImmunoGenesis, Inc., is a clinical stage immuno-oncology biopharmaceutical company re-envisioning "cold" tumor treatment. Representing more than half of all cancers, cold tumors lack activated T cells or have other immune resistance mechanisms, and current immunotherapies have shown limited to no efficacy. ImmunoGenesis' immune therapies are based in the pathology of these cold tumors, transforming them into hot tumors by targeting key mechanisms of immune resistance. For more information about the company, visit . Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as "will," "could," "believe," "plan," "expect," "target," "continue," "to," and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements regarding the development and/or effectiveness of evofosfamide and the ability of evofosfamide to achieve the desired results whether as a monotherapy or in combination with other therapies. We may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Contact Jennifer Guinan Sage Strategic Marketing 610-410-8111 [email protected] SOURCE ImmunoGenesis

CollaborateAntibodyImmunotherapy

31 May 2022

·www.globenewswire.com

Agenus Advances Portfolio with 6 Clinical Collaborations

LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that it has entered into 3 new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doubling its current number of clinical collaborations. These 6 collaborations span a range of Agenus’ clinical assets, including botensilimab (Fc-enhanced anti-CTLA-4), balstilimab (anti-PD-1), zalifrelimab (anti-CTLA-4), and QS-21 STIMULON™. Agenus is pursuing partnerships with companies developing agents with complementary mechanisms, paving the way for promising immunotherapy combinations to address immunosuppression in the tumor microenvironment. The combination studies are being sponsored and executed by our collaborators, with drug supply and scientific support provided by Agenus. This strategy, enabled by in-house integrated manufacturing and scientific capabilities, positions Agenus to achieve the insights and advances needed to drive development on accelerated timelines. “These new collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis are exciting next steps in our partnership strategy to broaden combinations and indications under evaluation with our immunomodulatory antibodies,” said Dr. Steven O’Day, Chief Medical Officer at Agenus. “We believe these combinations may unlock the power of immunotherapy more broadly, potentially offering new and promising benefit to patients with treatment-resistant solid tumors.” Agenus’ new and ongoing clinical collaborations are supporting and enabling: Targovax to conduct a clinical trial combining botensilimab and balstilimab with ONCOS-102 (oncolytic virus) in patients with PD-1 relapsed/refractory melanoma. ONCOS-102 is designed to induce immune activation and immunogenic cell death to improve response to immunotherapy.Oxford BioTherapeutics to conduct a clinical trial combining balstilimab with OBT076 (CD205-targeting antibody-drug conjugate) in patients with solid tumors, including lung, gastric, and ovarian cancer. OBT076 is expected to deplete CD205+ cancer cells, and immuno-suppressive cells within the tumor microenvironment, leading to T cell activation and increased response to immunotherapy.Immunogenesis to conduct a clinical trial combining balstilimab and zalifrelimab with evofosfamide (hypoxia-reversal agent) in patients with advanced solid tumors, including prostate, pancreatic, HPV-negative head and neck cancer. Evofosfamide is anticipated to reduce tumor hypoxia and restore T cell infiltration and activity within the tumor microenvironment, increasing responsiveness to checkpoint therapy.Targovax to conduct a clinical trial combining QS-21 STIMULON with TG01 (KRAS vaccine) in up to 3 cancer indications, including multiple myeloma. TG01 is designed to induce T cells that recognize and destroy mut-RAS cancer cells; QS-21 STIMULON is expected to improve immune cell recognition, activation, and TCR diversity of the immune response.Rottapharm Biotech is conducting a clinical trial combining balstilimab with CR6086 (EP4 antagonist) in patients with pMMR-MSS colorectal cancer. CR6086 is expected to inhibit the immune suppressive role of prostaglandins in the tumor microenvironment, improving immunogenicity and responsiveness to immunotherapy. The Phase 1/2 study commenced in 2021.Nelum is conducting a clinical trial combining zalifrelimab with NLM-001 (hedgehog inhibitor) and chemotherapy in patients with advanced pancreatic cancer. NLM-001 in combination with chemotherapy is anticipated to condition the tumor microenvironment to improve T cell infiltration, activation, and responsiveness to immunotherapy. The Phase 1/2 study commenced in 2021. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to the use of therapeutic candidates botensilimab, balstilimab, zalifrelimab, and QS-21 STIMULON, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety profile of the therapeutic candidates, both alone and in combination with each other and/or other agents; future clinical and regulatory development plans and commercialization plans for botensilimab, balstilimab, zalifrelimab, and QS-21 STIMULON; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: www.agenusbio.com. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Contact Ethan Lovell, Chief External Affairs & Communications OfficerAgenus Inc.339-927-1763ethan.lovell@agenusbio.com

CollaborateAntibodyCell TherapyVaccineImmunotherapy

100 Deals associated with Evofosfamide

External Link

KEGG	Wiki	ATC	Drug Bank
D10704	Evofosfamide	-	DB06091

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Phase 3	JP	Molecular Templates, Inc.	21 Dec 2012
Pancreatic Carcinoma	Phase 3	US	Threshold Pharmaceuticals, Inc.	01 Dec 2012
Pancreatic Carcinoma	Phase 3	DE	Threshold Pharmaceuticals, Inc.	01 Dec 2012
Pancreatic carcinoma non-resectable	Phase 3	US	Threshold Pharmaceuticals, Inc.	01 Dec 2012
Pancreatic carcinoma non-resectable	Phase 3	DE	Threshold Pharmaceuticals, Inc.	01 Dec 2012
Metastatic Soft Tissue Sarcoma	Phase 3	US	Threshold Pharmaceuticals, Inc.	01 Sep 2011
Metastatic Soft Tissue Sarcoma	Phase 3	AT	Threshold Pharmaceuticals, Inc.	01 Sep 2011
Metastatic Soft Tissue Sarcoma	Phase 3	BE	Threshold Pharmaceuticals, Inc.	01 Sep 2011
Metastatic Soft Tissue Sarcoma	Phase 3	CA	Threshold Pharmaceuticals, Inc.	01 Sep 2011
Metastatic Soft Tissue Sarcoma	Phase 3	DK	Threshold Pharmaceuticals, Inc.	01 Sep 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03098160 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Neoplasms	21	Ipilimumab+Evofosfamide	yicasasbgq(ulymhgagcj) = dxazqhzose celwzlgugj (vwjorpwwia ) View more	Positive	01 Jun 2021
Pubmed \| Sci Rep Manual	Phase 2	Recurrent Glioblastoma	33	evofosfamide+Bevacizumab	giucghhcan(cicolybslb) = gxbcgpkxup vwqthchfzc (hoyppxykcx ) View more	Positive	27 Jan 2021
NCT02402062 (GETNE-1408, CTgov)	Phase 2	Well Differentiated Pancreatic Endocrine Tumor \| Pancreatic neuroendocrine tumour metastatic	17	TH-302+Sunitinib	ynocmjrwnc(vjfbsmtxgj) = vfudsayeqc hrpqwfbwsq (sgidnblgju, fdziheilpn - wpocresber) View more	-	27 Jul 2020
NCT02342379 (CTgov)	Phase 2	Glioblastoma	35	TH-302+Bevacizumab	dcgoohqhum(irlubgvejk) = rgwquegfvi mleldmaycf (gjqdnlbztf, ynuxycjjiv - kmypgynocg) View more	-	10 Apr 2020
NCT03098160 (P348, SITC2019)	Phase 1	Advanced Malignant Solid Neoplasm	21	Evofosfamide 400mg/m2 + Ipilimumab 3mg/kg	pdwmtbyajz(zhpoukhqqd) = n=16 lafvzndxha (vtylzmqmbg ) View more	Positive	01 Nov 2019
NCT03098160 (P348, SITC2019)	Phase 1	Advanced Malignant Solid Neoplasm	21	Evofosfamide 480mg/m2 + Ipilimumab 3mg/kg		Positive	01 Nov 2019
EUCTR2014-004072-30-ES (SUNEVO, ESMO2019)	Phase 2	Pancreatic neuroendocrine tumour metastatic	17	Sunitinib + Evofosfamide	slgjdszels(azjqdofvxv) = kmwobfzpwk tfevvtfmng (pqntkuavse ) View more	-	30 Sep 2019
NCT01403610 (CTgov)	Phase 2	Astrocytoma \| High grade glioma	28	Placebo+TH-302 preoperative+bevacizumab 10mg/kg (Cohort 1)	yaqnsckzgu(hgzsvhphzk) = ifdooaauyz aekefblrnj (lrjebsfbjq, qfqijlgszk - ucdkykderz) View more	-	24 Jul 2019
NCT01403610 (CTgov)	Phase 2	Astrocytoma \| High grade glioma	28	TH-302 preoperative+bevacizumab 10mg/kg (Cohort 2)	yaqnsckzgu(hgzsvhphzk) = fgfdjdzqae aekefblrnj (lrjebsfbjq, gelwzkjudg - tjnjziduaq) View more	-	24 Jul 2019
NCT02402062 (ASCO2019) Manual	Phase 2	Pancreatic neuroendocrine tumour metastatic	17	evofosfamide+sunitinib	iylxqgjdsy(yrvztlxxza) = dfisboyvhw ktufydxjfr (vcbfleltkv ) View more	Negative	03 Jun 2019
NCT01522872 (Pubmed) Manual	Phase 1/2	Multiple Myeloma	59	dexamethasone+evofosfamide	pwqwigbyng(ubfocjpnbp) = fagohlsxtt ywgfogygga (nghpxymvtm ) View more	Positive	15 Jan 2019
NCT01522872 (Pubmed) Manual	Phase 1/2	Multiple Myeloma	59	dexamethasone+bortezomib+evofosfamide	zfllkbhagd(kfgrkmorws) = xrmclhmafw kniwrzygnl (jthbiihtpu ) View more	Positive	15 Jan 2019
NCT02255110 (CTgov)	Phase 2	Metastatic Soft Tissue Sarcoma	6	TH-302+doxorubicin	ghsaspwlsv(zmrdqfiule) = stromxozeu peyqitwpdz (wqivlbkdyr, fwdglnecuz - axpzcwmzry) View more	-	14 Dec 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis